E-resources
Peer reviewed
Open access
-
Oki, Ryosuke; Izumi, Yuishin; Fujita, Koji; Miyamoto, Ryosuke; Nodera, Hiroyuki; Sato, Yasutaka; Sakaguchi, Satoshi; Nokihara, Hiroshi; Kanai, Kazuaki; Tsunemi, Taiji; Hattori, Nobutaka; Hatanaka, Yuki; Sonoo, Masahiro; Atsuta, Naoki; Sobue, Gen; Shimizu, Toshio; Shibuya, Kazumoto; Ikeda, Ken; Kano, Osamu; Nishinaka, Kazuto; Kojima, Yasuhiro; Oda, Masaya; Komai, Kiyonobu; Kikuchi, Hitoshi; Kohara, Nobuo; Urushitani, Makoto; Nakayama, Yoshiaki; Ito, Hidefumi; Nagai, Makiko; Nishiyama, Kazutoshi; Kuzume, Daisuke; Shimohama, Shun; Shimohata, Takayoshi; Abe, Koji; Ishihara, Tomohiko; Onodera, Osamu; Isose, Sagiri; Araki, Nobuyuki; Morita, Mitsuya; Noda, Kazuyuki; Toda, Tatsushi; Maruyama, Hirofumi; Furuya, Hirokazu; Teramukai, Satoshi; Kagimura, Tatsuo; Noma, Kensuke; Yanagawa, Hiroaki; Kuwabara, Satoshi; Kaji, Ryuji
JAMA neurology, 06/2022, Volume: 79, Issue: 6Journal Article
The effectiveness of currently approved drugs for amyotrophic lateral sclerosis (ALS) is restricted; there is a need to develop further treatments. Initial studies have shown ultrahigh-dose methylcobalamin to be a promising agent. To validate the efficacy and safety of ultrahigh-dose methylcobalamin for patients with ALS enrolled within 1 year of onset. This was a multicenter, placebo-controlled, double-blind, randomized phase 3 clinical trial with a 12-week observation and 16-week randomized period, conducted from October 17, 2017, to September 30, 2019. Patients were recruited from 25 neurology centers in Japan; those with ALS diagnosed within 1 year of onset by the updated Awaji criteria were initially enrolled. Of those, patients fulfilling the following criteria after 12-week observation were eligible for randomization: 1- or 2-point decrease in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score, a percent forced vital capacity greater than 60%, no history of noninvasive respiratory support and tracheostomy, and being ambulatory. The target participant number was 64 in both the methylcobalamin and placebo groups. Patients were randomly assigned through an electronic web-response system to methylcobalamin or placebo. Intramuscular injection of methylcobalamin (50-mg dose) or placebo twice weekly for 16 weeks. The primary end point was change in ALSFRS-R total score from baseline to week 16 in the full analysis set. A total of 130 patients (mean SD age, 61.0 11.7 years; 74 men 56.9%) were randomly assigned to methylcobalamin or placebo (65 each). A total of 129 patients were eligible for the full analysis set, and 126 completed the double-blind stage. Of these, 124 patients proceeded to the open-label extended period. The least square means difference in ALSFRS-R total score at week 16 of the randomized period was 1.97 points greater with methylcobalamin than placebo (-2.66 vs -4.63; 95% CI, 0.44-3.50; P = .01). The incidence of adverse events was similar between the 2 groups. Results of this randomized clinical trial showed that ultrahigh-dose methylcobalamin was efficacious in slowing functional decline in patients with early-stage ALS and with moderate progression rate and was safe to use during the 16-week treatment period. ClinicalTrials.gov Identifier: NCT03548311.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.